- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1153–1176
of 4,019
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumors
- Interventions
- Paclitaxel, RO5509554
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
- Interventions
- Pembrolizumab, Axitinib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Healthy Adult Subjects
- Interventions
- Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Adult Glioblastoma
- Interventions
- Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide
- Other · Biological · Radiation + 1 more
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma
- Interventions
- Part 1 (Dose Escalation): Daratumumab, Part 2 (Dose Expansion): Daratumumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Amputation Stump
- Interventions
- Prosthetic socket for transtibial amputee
- Device
- Lead sponsor
- Massachusetts Institute of Technology
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Adenocarcinoma, Neoplasms
- Interventions
- Torisel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 8 more
- Conditions
- Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration, Neovascularization, Pathologic
- Interventions
- OPT-302, Lucentis™
- Drug
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more
- Conditions
- Myeloma
- Interventions
- Lenalidomide, Dexamethasone, All-Trans Retinoic Acid (ATRA)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors (Phase 1), Relapsed/Recurrent GBM (Phase 2)
- Interventions
- USL311, Lomustine
- Drug
- Lead sponsor
- Proximagen, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 5
- States / cities
- St Louis, Missouri • Oklahoma City, Oklahoma • Houston, Texas + 1 more
- Conditions
- Cutaneous Melanoma, Brain Metastases
- Interventions
- Defactinib, Avutometinib, Encorafenib
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Salt Lake City, Utah
- Conditions
- HIV Infections
- Interventions
- Cabotegravir sodium (Oral Lead In), Cabotegravir 400 mg/mL, Cabotegravir 200 mg/mL, Topical Non-steroidal anti-inflammatory drug (NSAID), Topical steroid, Topical NSAID placebo, Recombinant human hyaluronidase PH20 (rHuPH20), Topical steroid placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Las Vegas, Nevada • Berlin, New Jersey + 1 more
- Conditions
- Social Media Literacy
- Interventions
- interactive website
- Other
- Lead sponsor
- Boston University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pediatric Cancer, Neuroblastoma, Sarcoma, Wilms Tumor and Other Childhood Kidney Tumors, Childhood Soft Tissue Sarcoma, Childhood Bone Sarcoma, Childhood Malignant Intestinal Neoplasm, Childhood Malignant Liver Neoplasm, Childhood Malignant Lung Neoplasm, Childhood Malignant Ovarian Neoplasm, Childhood Malignant Pleural Neoplasm, Childhood Neuroblastic Tumor, Childhood Sarcoma
- Interventions
- Wearing Smartwatch, Patient Report Outcomes, Blood Draw, Clinical Data Review
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Paroxysmal Supraventricular Tachycardia
- Interventions
- Etripamil, Placebo, Etripamil Test Dose
- Drug
- Lead sponsor
- Milestone Pharmaceuticals Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,097 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more
- Conditions
- Vaccine Refusal, Covid19
- Interventions
- COVID-19 Individual Awareness and Education., COVID-19 Community Outreach & Health Promotion., COVID-19 Individual Health Education & Linkages to Medical and Supportive Services., Pop-up community vaccination sites
- Behavioral · Biological
- Lead sponsor
- Britt Skaathun
- Other
- Eligibility
- 16 Years to 99 Years
- Enrollment
- 1,051 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 6
- States / cities
- Chula Vista, California • San Diego, California • San Ysidro, California
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer
- Interventions
- Etrumadenant, Zimberelimab
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Coronary Artery Disease
- Interventions
- Image Quality, Diagnostic Accuracy
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cystic Fibrosis
- Interventions
- AZD5634 for inhalation, AZD5634 for infusion, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Uremic Pruritus
- Interventions
- CR845 0.5 mcg/kg, CR845 1 mcg/kg, CR845 1.5mcg/kg, Placebo
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Pine Bluff, Arkansas • Long Beach, California + 23 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Virta Health
- Behavioral
- Lead sponsor
- Colorado Prevention Center
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Craig, Colorado • Lamar, Colorado • Salida, Colorado
- Conditions
- AL Amyloidosis
- Interventions
- CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
- Drug · Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- RAD001, Imatinib
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan